Corcept Therapeutics (CORT) Equity Average (2011 - 2026)

Corcept Therapeutics has disclosed Equity Average across 16 years of filings, most recently posting $642.9 million for Q1 2026.

• Equity Average for Q1 2026 came in at $642.9 million, down 5.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $642.9 million (down 5.66% YoY), and the FY2025 annual result was $663.7 million, up 11.89% from the prior year.
• Equity Average came in at $642.9 million for Q1 2026 at Corcept Therapeutics, roughly flat from $639.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $681.4 million in Q1 2025 to a low of $391.8 million in Q1 2022.
• The 5-year median for Equity Average is $527.3 million (2024), against an average of $547.8 million.
• Across the five-year window, Equity Average declined 24.23% in 2022 and jumped 39.83% in 2024, its largest moves.
• Corcept Therapeutics' Equity Average stood at $487.6 million in 2022, then decreased by 0.7% to $484.2 million in 2023, then soared by 36.15% to $659.2 million in 2024, then fell by 2.94% to $639.9 million in 2025, then gained by 0.48% to $642.9 million in 2026.
• The last three Equity Average figures came in at $642.9 million (Q1 2026), $639.9 million (Q4 2025), and $633.8 million (Q3 2025), per Business Quant data.